In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein (a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein (a) threshold to guide therapy.

2021年2月1日 · This review aims to summarize the most update knowledge about the mechanisms of LPA production and signaling in order to understand its biological functions in the central nervous system both in...

2023年11月28日 · 本文主要概述了Lp (a)与心血管疾病（CVD）关系、定量检测以及相关药物和指南共识推荐。 Lp (a)是ASCVD和钙化性瓣膜性主动脉瓣狭窄的独立危险因素。 Lp (a)表现出显著的种族/族裔差异，其中非洲血统人群中水平最高。 Lp (a)水平通常在5岁后不会改变，除非在出现严重炎症、肝病或肾病期间；因此，在这段时间里，应谨慎解释水平。 目前的指南支持对大多数ASCVD风险增加的个体进行一生一次的检测。 新的数据似乎显示，高敏C反应蛋 …

LOSS PREVENTION ASIA (LPA) 2021 is the 2 nd International Conference and Exhibition organised by Centre of Advanced Process Safety (CAPS), Universiti Teknologi PETRONAS (UTP) and in collaboration with PETRONAS (Self-Regulation Task Force) and Department of Occupational Safety and Health (DOSH).

LPA GROUP PLC . LPA Group plc (“LPA” or the “Group”), the high reliability LED lighting, electronic and electro-mechanical system designer and manufacturer, announces its Preliminary Results for the year ended 30 September 2021. Preliminary Results key points: Financial • Order Entry increased to £23.2m (2020: £21.9m)

2021年7月6日 · LPA Group Plc (LPA) 2021年年度报告「LSE」.pdf，点击即可下载。 包含的报告内容，文档格式为PDF，大小1.59MB，页数112页，字数约246654字，欢迎会员下载 三个皮匠报告—— 严选型全行业研究报告分享下载平台，您的专属行业智库！

Lipoprotein (a) [Lp (a)] is an atherogenic lipoprotein with a strong genetic regulation. Up to 90% of the concentrations are explained by a single gene, the LPA gene. The concentrations show a several-hundred-fold interindividual variability ranging from less than 0.1 mg/dL to …

2024年5月1日 · In this review, we provide the roles of LPA receptor-mediated signaling in the regulation of cellular responses induced by chemotherapeutic agents and irradiation and its biological utility as a possible molecular target for improving cancer cell responses to chemotherapy and radiotherapy. 1. Introduction.

2021年11月30日 · In this report, we use metabolic profiles as the fingerprint to investigate key lipid components in AlbuMAX and identify signaling lipid lysophosphatidic acid (LPA) as the key factor to shift the metabolic landscape. We then show that primed pluripotency is maintained independent of lipid supplements or the level of de novo lipogenesis.

Over the past decade, elevated lipoprotein (a) [Lp (a)] has gone from a curious and relatively unknown atherosclerotic cardiovascular disease (ASCVD) risk factor to one that has reached the forefront of cardiovascular risk prevention.